BRPI0719865A2 - molécula de ácido nucleico, proteína de fusão purificada, vetor, célula hospedeira, processo para expressar uma proteína de fusão, e, método para tratar um paciente sofrendo de ou predisposto a um câncer - Google Patents
molécula de ácido nucleico, proteína de fusão purificada, vetor, célula hospedeira, processo para expressar uma proteína de fusão, e, método para tratar um paciente sofrendo de ou predisposto a um câncerInfo
- Publication number
- BRPI0719865A2 BRPI0719865A2 BRPI0719865A BRPI0719865A BRPI0719865A2 BR PI0719865 A2 BRPI0719865 A2 BR PI0719865A2 BR PI0719865 A BRPI0719865 A BR PI0719865A BR PI0719865 A BRPI0719865 A BR PI0719865A BR PI0719865 A2 BRPI0719865 A2 BR PI0719865A2
- Authority
- BR
- Brazil
- Prior art keywords
- tert
- fusion protein
- fusion proteins
- vector
- cancer
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 6
- 108020001507 fusion proteins Proteins 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 108010017842 Telomerase Proteins 0.000 abstract 12
- 102100032938 Telomerase reverse transcriptase Human genes 0.000 abstract 11
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 201000009030 Carcinoma Diseases 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 101710146739 Enterotoxin Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000003197 catalytic effect Effects 0.000 abstract 1
- 239000000147 enterotoxin Substances 0.000 abstract 1
- 231100000655 enterotoxin Toxicity 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85118306P | 2006-10-12 | 2006-10-12 | |
| PCT/EP2007/060713 WO2008043760A1 (en) | 2006-10-12 | 2007-10-09 | Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0719865A2 true BRPI0719865A2 (pt) | 2016-03-15 |
Family
ID=38858912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0719865A BRPI0719865A2 (pt) | 2006-10-12 | 2007-10-09 | molécula de ácido nucleico, proteína de fusão purificada, vetor, célula hospedeira, processo para expressar uma proteína de fusão, e, método para tratar um paciente sofrendo de ou predisposto a um câncer |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8017387B2 (pt) |
| EP (1) | EP2076531B1 (pt) |
| JP (1) | JP2010505433A (pt) |
| KR (1) | KR20090079938A (pt) |
| CN (1) | CN101522706B (pt) |
| AT (1) | ATE534661T1 (pt) |
| AU (1) | AU2007306368B2 (pt) |
| BR (1) | BRPI0719865A2 (pt) |
| CA (1) | CA2664168A1 (pt) |
| ES (1) | ES2376010T3 (pt) |
| IL (1) | IL198012A0 (pt) |
| MX (1) | MX2009003873A (pt) |
| NO (1) | NO20091840L (pt) |
| NZ (1) | NZ576134A (pt) |
| RU (1) | RU2473691C2 (pt) |
| WO (1) | WO2008043760A1 (pt) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3184778A1 (en) * | 2006-07-28 | 2008-01-31 | The Trustees Of The University Of Pennsylvania | Hiv consensus envelope sequences and methods for using same |
| EP2324057B1 (en) * | 2008-08-12 | 2018-03-21 | MSD Italia S.r.l. | Minigene comprising htpa signal peptide, t-cell epitopes, e. coli ltb and furin sensitive linkers |
| EP2639299A1 (en) | 2012-03-16 | 2013-09-18 | Invectys | Universal cancer peptides derived from telomerase |
| US20150125438A1 (en) * | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
| CN102942618B (zh) * | 2012-11-14 | 2014-05-21 | 中国人民解放军军事医学科学院生物工程研究所 | 具有肿瘤细胞杀伤活性的端粒蛋白多肽片段及其应用 |
| WO2014144885A2 (en) * | 2013-03-15 | 2014-09-18 | The Trustees Of The University Of Pennsylvania | Cancer vaccines and methods of treatment using the same |
| WO2014154904A1 (en) | 2013-03-28 | 2014-10-02 | Invectys | A cancer vaccine for cats |
| WO2014154905A1 (en) | 2013-03-28 | 2014-10-02 | Invectys | A cancer vaccine for dogs |
| US9757473B2 (en) * | 2013-07-12 | 2017-09-12 | Gemvax & Kael Co., Ltd. | Cell-penetrating peptide and conjugate comprising same |
| DK3063280T3 (da) | 2013-10-28 | 2019-11-11 | Invectys | Genelektrooverførsel ind i hudceller |
| US10183065B2 (en) * | 2013-10-28 | 2019-01-22 | Invectys | Telomerase encoding DNA vaccine |
| KR102494803B1 (ko) * | 2013-11-22 | 2023-02-06 | 주식회사 젬백스앤카엘 | 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
| US10370723B2 (en) | 2014-07-17 | 2019-08-06 | Blueprint Medicines Corporation | TERT fusions |
| JP7572700B2 (ja) * | 2015-10-19 | 2024-10-24 | ユニバーシティ オブ メリーランド ボルチモア | 改変ヒト初代血液樹状細胞株を生成するための方法 |
| ES2811523T3 (es) * | 2016-01-19 | 2021-03-12 | Pfizer | Vacunas contra el cáncer |
| MX2018009506A (es) * | 2016-02-05 | 2019-05-06 | Inovio Pharmaceuticals Inc | Vacunas contra el cáncer y métodos de tratamiento que las utilizan. |
| WO2018064588A2 (en) * | 2016-09-30 | 2018-04-05 | Weiner, David | Tert immunogenic compositions and methods of treatment using the same |
| WO2018206512A1 (en) | 2017-05-09 | 2018-11-15 | Invectys | Recombinant measles vaccine expressing htert |
| CN111065408A (zh) * | 2017-07-11 | 2020-04-24 | 辉瑞公司 | 免疫原性组合物 |
| CA3122259A1 (en) * | 2018-12-05 | 2020-06-11 | Linearx, Inc. | Amplicon expression vector vaccines |
| EP4333887A4 (en) * | 2021-05-05 | 2025-05-21 | Inovio Pharmaceuticals, Inc. | Vaccines against coronavirus and methods of use |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1340372C (en) | 1984-07-09 | 1999-02-02 | John D. Clements | Production of e. coli lt-b enterotoxin subunit |
| CA2004738A1 (en) | 1988-12-07 | 1990-06-07 | University Of Leicester | Heat-labile toxin b subunit fusion proteins |
| US6413523B1 (en) | 1989-06-02 | 2002-07-02 | The United States Of America As Represented By The Secretary Of The Navy | Pharmaceutical composition of escherichia coli heat-labile enterotoxin adjuvant and methods of use |
| US5241053A (en) | 1990-09-05 | 1993-08-31 | Takeda Chemical Industries, Ltd. | Fused proteins comprising glycoprotein gD of HSV-1 and LTB |
| US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
| US6093809A (en) | 1996-10-01 | 2000-07-25 | University Technology Corporation | Telomerase |
| US7585622B1 (en) | 1996-10-01 | 2009-09-08 | Geron Corporation | Increasing the proliferative capacity of cells using telomerase reverse transcriptase |
| CN1254376A (zh) | 1996-10-01 | 2000-05-24 | 杰龙公司 | 端粒酶逆转录酶 |
| US6475789B1 (en) | 1996-10-01 | 2002-11-05 | University Technology Corporation | Human telomerase catalytic subunit: diagnostic and therapeutic methods |
| US7390891B1 (en) * | 1996-11-15 | 2008-06-24 | Amgen Inc. | Polynucleotides encoding a telomerase component TP2 |
| WO1998037181A2 (en) | 1997-02-20 | 1998-08-27 | Whitehead Institute For Biomedical Research | Telomerase catalytic subunit gene and encoded protein |
| US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
| US7622549B2 (en) | 1997-04-18 | 2009-11-24 | Geron Corporation | Human telomerase reverse transcriptase polypeptides |
| JP2002508662A (ja) | 1997-06-20 | 2002-03-19 | バイエル・アクチエンゲゼルシヤフト | ヒトテロメラーゼの触媒サブユニット並びにその診断的及び治療的使用 |
| EP0919243A1 (en) * | 1997-11-25 | 1999-06-02 | Duphar International Research B.V | Vaccine containing B subunits of heat-labile enterotoxin (LTB) of Escherichia coli as an adjuvant |
| US6733993B2 (en) | 2000-09-15 | 2004-05-11 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications |
| ATE467680T1 (de) | 2001-10-11 | 2010-05-15 | Merck Sharp & Dohme | Hepatitis-c-virus-impfstoff |
| AU2003249357A1 (en) * | 2002-06-27 | 2004-01-19 | Geron Corporation | Cancer vaccine containing cross-species epitopes of telomerase reverse transcriptase |
| ES2387850T3 (es) * | 2004-02-11 | 2012-10-02 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. | Proteína de fusión al antígeno carcinoembrionario y sus usos |
| DE102004035227A1 (de) * | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
| WO2006011151A2 (en) | 2004-07-28 | 2006-02-02 | Gavish - Galilee Bio Applications Ltd. | Vaccine comprising recombinant ct or lt toxin |
| MX2007014390A (es) | 2005-05-19 | 2008-02-12 | Glaxosmithkline Biolog Sa | Composicion de vacuna que comprende subunidad b de termo toxina e. coli y antigeno y adyuvante. |
| CN1757736A (zh) * | 2005-07-26 | 2006-04-12 | 浙江大学 | 一种融合基因载体的构建表达及应用 |
-
2007
- 2007-10-09 AT AT07821082T patent/ATE534661T1/de active
- 2007-10-09 NZ NZ576134A patent/NZ576134A/en not_active IP Right Cessation
- 2007-10-09 CN CN2007800378827A patent/CN101522706B/zh not_active Expired - Fee Related
- 2007-10-09 KR KR1020097009725A patent/KR20090079938A/ko not_active Ceased
- 2007-10-09 EP EP07821082A patent/EP2076531B1/en active Active
- 2007-10-09 AU AU2007306368A patent/AU2007306368B2/en not_active Ceased
- 2007-10-09 RU RU2009117325/10A patent/RU2473691C2/ru not_active IP Right Cessation
- 2007-10-09 JP JP2009531827A patent/JP2010505433A/ja active Pending
- 2007-10-09 CA CA002664168A patent/CA2664168A1/en not_active Abandoned
- 2007-10-09 MX MX2009003873A patent/MX2009003873A/es active IP Right Grant
- 2007-10-09 BR BRPI0719865A patent/BRPI0719865A2/pt not_active IP Right Cessation
- 2007-10-09 WO PCT/EP2007/060713 patent/WO2008043760A1/en not_active Ceased
- 2007-10-09 ES ES07821082T patent/ES2376010T3/es active Active
- 2007-10-11 US US11/974,067 patent/US8017387B2/en not_active Expired - Fee Related
-
2009
- 2009-04-05 IL IL198012A patent/IL198012A0/en unknown
- 2009-05-11 NO NO20091840A patent/NO20091840L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20091840L (no) | 2009-07-10 |
| AU2007306368B2 (en) | 2012-05-03 |
| RU2009117325A (ru) | 2010-11-20 |
| ES2376010T3 (es) | 2012-03-08 |
| IL198012A0 (en) | 2011-08-01 |
| EP2076531A1 (en) | 2009-07-08 |
| US8017387B2 (en) | 2011-09-13 |
| ATE534661T1 (de) | 2011-12-15 |
| RU2473691C2 (ru) | 2013-01-27 |
| CN101522706B (zh) | 2013-09-04 |
| JP2010505433A (ja) | 2010-02-25 |
| CN101522706A (zh) | 2009-09-02 |
| NZ576134A (en) | 2011-09-30 |
| MX2009003873A (es) | 2009-04-22 |
| AU2007306368A1 (en) | 2008-04-17 |
| CA2664168A1 (en) | 2008-04-17 |
| EP2076531B1 (en) | 2011-11-23 |
| WO2008043760A1 (en) | 2008-04-17 |
| KR20090079938A (ko) | 2009-07-22 |
| US20080090778A1 (en) | 2008-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20091840L (no) | Telomerase-reverstranskriptase-fusjonsprotein, nukleotider som koder for det, og anvendelser derav | |
| BRPI0507579A (pt) | molécula de ácido nucleico, vetor, célula hospedeira, processo para expressar uma proteìna de fusão cea em uma célula hospedeira recombinante, proteìna de fusão cea purificada, método de prevenção ou tratamento de cáncer, plasmìdeo de vacina, e, método de tratamento de um mamìfero sofrendo de ou predisposto a um cáncer associados com cea | |
| EA200700849A1 (ru) | Первичная/бустерная противомалярийная вакцина | |
| BRPI0407233A (pt) | Anticorpo neutralizante, molécula de anticorpo, anticorpo enxertado em cdr, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção da molécula de anticorpo, e, composição farmacêutica | |
| WO2006089230A3 (en) | Human monoclonal antibodies to prostate specific membrane antigen (psma) | |
| BRPI0807929A2 (pt) | Anticorpo monoclonal humano isolado ou porção de ligação de antígeno do mesmo, polipeptídeo isolado, composição, ácido nucleico isolado, vetor de expressão, célula hospedeira, vacina do vírus da hepatite c (hcv), kit, métodos para tratar e detectar uma infecção por vírus da hepatite c (hcv) e para identificar um anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo, e, proteína e2 recombinante do vírus da hepatite c (hcv) | |
| CY1117236T1 (el) | Μονοκλωνικα αντισωματα εναντι γλυπικανης-3 | |
| DE60044665D1 (de) | Her2/neu fusionsproteine | |
| UA100682C2 (ru) | АНТИТЕЛО, КОТОРОЕ НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ ЦИТОМЕГАЛОВИРУС (hCMV), И ЕГО ПРИМЕНЕНИЕ | |
| MX2024004293A (es) | Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika. | |
| UA97516C2 (ru) | Полностью человеческое моноклональное антитело против vap-1 | |
| BRPI0619595B8 (pt) | anticorpo neutralizante, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção de um anticorpo, composição farmacêutica, e, uso de um anticorpo neutralizante humanizado | |
| WO2005120565A3 (en) | Sars vaccines and methods to produce highly potent antibodies | |
| Duan et al. | A novel disulfide-stabilized single-chain variable antibody fragment against rabies virus G protein with enhanced in vivo neutralizing potency | |
| WO2008118487A3 (en) | Compositions and methods for incresing immunogenicity of glycoprotein vaccines | |
| ATE470673T1 (de) | Impfstoffe mit lawsoniaintrazellularis- untereinheit | |
| DK1536006T3 (da) | Cancerantigener og anvendelse deraf | |
| BRPI0511793B8 (pt) | proteínas quiméricas isoladas de lumazina sintase modificada | |
| ATE450545T1 (de) | Impfstoff mit lawsonia intracellularis- untereinheit | |
| Seok et al. | Conformational modulation of influenza virus hemagglutinin: characterization and in vivo efficacy of monomeric form | |
| ATE417106T1 (de) | Chlamydia antigene und deren korrespondierende dna fragmente und verwendungen davon | |
| Patel et al. | Escherichia coli-based production of a tumor idiotype antibody fragment–tetanus toxin fragment C fusion protein vaccine for B cell lymphoma | |
| Nazeri et al. | Engineering M13 bacteriophage to display HER2 mimotopes on pVIII for vaccine development | |
| Samal et al. | Tetramerizing tGCN4 domain facilitates production of Influenza A H1N1 M2e higher order soluble oligomers that show enhanced immunogenicity in vivo | |
| ATE448245T1 (de) | Piroplasmid-impfstoff |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 8A E 9A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |